Last reviewed · How we verify
NCT00906646: MPM
Preparation of Patients for Cardiac Surgery
Phase 3 trial testing Metabolic therapy in Coronary Artery Bypass Graft Surgery in 117 participants. Completed in 1 December 2008.
1 June 2006
Quick facts
| Lead sponsor | Bayside Health |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 117 |
| Start date | 1 April 2004 |
| Primary completion | 1 June 2006 |
| Estimated completion | 1 December 2008 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Metabolic therapy
- Placebo
Conditions studied
- Coronary Artery Bypass Graft Surgery — all drugs for Coronary Artery Bypass Graft Surgery →
- Cardiac Valve Surgery — all drugs for Cardiac Valve Surgery →
Sponsor
Bayside Health — full company profile →
Who can join
Eligibility, any sex, with Coronary Artery Bypass Graft Surgery or Cardiac Valve Surgery. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Troponin release
Time frame: 24 hours after surgery
Sponsor's own description
This was a prospective randomised trial of metabolic therapy including antioxidants and cellular energisers to determine whether this therapy could improve the results of cardiac surgery. The hypothesis was that the metabolic therapy could improve clinical recovery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00906646
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Bypass Graft Surgery
Currently open trials in the same condition.
- NCT07035756 — Development of an Arterial Pressure Monitoring Set Fixation Apparatus · NA · recruiting
Other Bayside Health trials
Trials by the same sponsor.
- NCT05852301 — Optimising Cohorts for HIV Cure Interventions · unknown
- NCT05470816 — Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial · Phase 3 · active not recruiting
- NCT04192435 — Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery · Phase 4 · completed
- NCT04978285 — Association of Postoperative Anaemia With Patient-centred Outcomes · completed
- NCT03869736 — Nitrous Oxide for the Treatment of Major Depressive Disorder · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00906646 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayside Health
- Last refreshed: 20 May 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00906646.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing